<p>首個可穿戴肽貼片旨在將 BPC-157 從注射劑擴展到多產品經皮肽平台，隸屬於 Amino Innovations</p>
<p>加拿大不列顛哥倫比亞省温哥華 --（Newsfile Corp. -2026 年 5 月 7 日）-- <strong>精準肽公司 (CSE: BPC) (OTCQB: PNGAF) (以下簡稱 “公司” 或 “BPC”)</strong>，一家專注於先進肽配方和輸送系統的上市健康公司，今天提供了關於其無針 BPC-157 經皮貼片開發的最新進展——這一產品旨在為消費者首次提供無摩擦的肽類產品進入途徑。</p>
<p>BPC-157 貼片目前正在積極測試中，預計近期將有結果。若這些測試里程碑順利完成，公司計劃將該產品推進至商業發佈階段，作為精準肽公司產品組合的一部分。</p>
<p>數十年來，肽類產品一直受到針頭的限制。儘管在恢復、長壽和更廣泛的健康領域對肽的興趣迅速增長，但大多數消費者從未跨越進入這一領域的門檻——研究一致表明，針頭恐懼是消費者本可以考慮的療法的主要障礙。因此，採用者主要集中在已經習慣自我注射的生物黑客、運動員和臨牀人羣中。</p>
<p>這一創新貼片旨在完全消除這一障礙。直接貼在皮膚上，經過精確設計以實現控制和持續的肽輸送，該貼片消除了與注射肽療法相關的重組、無菌處理和劑量測量。最終結果是一個可穿戴的、適合主流市場的格式，旨在將 BPC-157 和其他配方帶給那些遠觀肽類產品並一直在等待他們實際會使用的輸送格式的消費者。</p>
<p>精準肽公司的首席執行官 Pratap Sandhu 評論道：</p>
<p>“這是將肽帶入主流的產品。針頭歷來是這一領域最大的進入障礙，去除它從根本上改變了客户的面貌。該貼片是為那些閲讀過頭條新聞、聽過播客並決定肽不適合他們的人設計的，因為他們不願意注射。我們相信它是肽類產品的起源與更大消費者市場之間的橋樑，而迄今為止的測試進展支持了我們對這一路徑的信心。”</p>
<p>Amino Innovations 的首席科學官 Justin Kirkland 補充道：</p>
<p>“BPC-157 背後有數十年的臨牀前研究，將該分子從注射劑轉化為經皮格式是一項重要的配方工作。該貼片經過設計，能夠以可靠的方式通過皮膚持續輸送，表現出在非注射環境下的可靠性。我們通過這一測試項目生成的數據使我們對該貼片作為傳統肽給藥的可信、可擴展替代品充滿信心——在我們看來，這是該類別如何接觸日常消費者的一大進步。”</p>
<p>BPC-157 貼片是公司更廣泛的經皮貼片管道中首個推進的產品。第二個貼片——公司的免疫防禦貼片，採用胸腺素 Alpha-1 (TA-1) 配方，並在相同的輸送平台上開發，也在開發中，預計將在測試後跟隨 BPC-157 走向商業準備。兩個產品共同旨在建立一個無針肽類產品的多產品平台，隸屬於 Amino Innovations 品牌。</p>
<p>貼片開發得到了公司之前與阿爾伯塔大學藥物開發與創新中心 (DDIC) 簽署的研究服務協議的支持，Neal Davies 博士和 Raimar Loebenberg 博士是藥學與藥物科學學院的高級教授，提供與公司肽產品組合相關的吸收、生物利用度和穩定性方面的科學專業知識。</p>
<p>BPC-157 貼片將與公司現有的口服肽產品線並列，該產品線在美國獲得批准的設施中生產，並通過 Amino Innovations 品牌在北美分銷。</p>
<p>目前正在進行的測試無法保證會產生滿足公司內部基準的結果，BPC-157 貼片或免疫防禦貼片是否會在當前預期的時間表上商業化，或任何後續產品發佈是否會為公司帶來收入或其他利益。公司將在發生重大進展時提供進一步更新。</p>
<p><strong>關於精準肽公司</strong></p>
<p>精準肽公司 (CSE: BPC) (OTCQB: PNGAF) 是一家上市健康公司，正在建立一個高質量肽配方的下一代平台。通過結合科學配方和創新輸送技術，公司創造出位於生物技術與可擴展消費者健康交匯處的產品。產品在美國獲得批准的設施中生產，並在北美分銷。</p>
<p>欲瞭解更多信息，請訪問：www.precisionpeptidecompany.com</p>
<p><strong>關於前瞻性信息的警示説明</strong></p>
<p><strong>本新聞稿包含適用的加拿大證券法意義上的 “前瞻性信息”。前瞻性信息包括但不限於與以下內容相關的聲明：對 BPC-157 透皮貼片測試的預期時間和結果；公司推進 BPC-157 貼片商業發佈的意圖；免疫防禦貼片的預期開發和商業化；在 Amino Innovations 品牌下建立多產品無針肽平台；以及公司與阿爾伯塔大學藥物開發與創新中心（DDIC）研究服務協議的預期收益。</strong></p>
<p><strong>前瞻性信息基於公司做出的某些關鍵期望和假設，包括：BPC-157 貼片的測試將按照當前設想的時間表進行，併產生與公司內部基準一致的結果；沒有不利的監管、科學、製造或供應鏈發展會實質性延遲或阻止公司產品的商業化；與 DDIC 的研究服務協議將繼續保持當前形式；以及一般商業和經濟條件不會以對公司不利的方式發生變化。</strong></p>
<p><strong>儘管公司相信前瞻性信息所基於的期望和假設是合理的，但不應對前瞻性信息過度依賴，因為公司無法保證這些信息將被證明是正確的。由於前瞻性信息涉及未來事件和條件，其本質上涉及固有的風險和不確定性。實際結果可能因多種因素和風險而與當前預期大相徑庭，包括但不限於：BPC-157 貼片測試未能產生令人滿意的結果的風險；公司無法在當前設想的時間表內，或根本無法商業化 BPC-157 貼片或免疫防禦貼片的風險；BPC-157 的透皮給藥未能實現足夠的生物利用度或消費者接受度的風險；以及任何後續產品發佈未能為公司帶來收入或其他收益的風險。</strong></p>
<p><strong>本新聞稿中包含的前瞻性信息截至本日期發佈，公司沒有義務公開更新或修訂任何前瞻性信息，無論是由於新信息、未來事件還是其他原因，除非適用的證券法要求。</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8944/296392_c538c1950414bba7_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8944/296392_c538c1950414bba7_logo.jpg"/></p>
<p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/296392</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296392/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296392/375"/></p>

PRAX

標普全球醫療股指數 ETF - iShares

動態生物技術與基因組 ETF - Invesco

<p>精準肽公司即將商業推出其無針 BPC-157 透皮貼片，旨在通過消除注射的需要，使肽療法更易於獲取。目前該貼片正在積極測試中，旨在實現肽的控制釋放，並瞄準更廣泛的消費者市場。公司還計劃開發其他貼片，包括免疫防禦貼片。首席執行官 Pratap Sandhu 強調，這一創新可能會顯著改變消費者與肽療法的互動。公司正在與阿爾伯塔大學合作，為貼片的開發提供科學支持</p>

<p>First wearable peptide patch designed to expand BPC-157 beyond injectables and establish a multi-product transdermal peptide platform under Amino Innovations</p>
<div class="lb-trans"><p>首個可穿戴肽貼片旨在將 BPC-157 從注射劑擴展到多產品經皮肽平台，隸屬於 Amino Innovations</p>
</div><p>Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - <strong>The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the &#34;Company&#34; or &#34;BPC&#34;)</strong>, a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today provides an update on the development of its needle-free BPC-157 transdermal patch - a product designed to give consumers a frictionless route into the peptide category for the first time.</p>
<div class="lb-trans"><p>加拿大不列顛哥倫比亞省温哥華 --（Newsfile Corp. -2026 年 5 月 7 日）-- <strong>精準肽公司 (CSE: BPC) (OTCQB: PNGAF) (以下簡稱 “公司” 或 “BPC”)</strong>，一家專注於先進肽配方和輸送系統的上市健康公司，今天提供了關於其無針 BPC-157 經皮貼片開發的最新進展——這一產品旨在為消費者首次提供無摩擦的肽類產品進入途徑。</p>
</div><p>The BPC-157 patch is currently in active testing, with results anticipated in the near term. Subject to the satisfactory completion of these testing milestones, the Company intends to progress the product closer to commercial release as part of The Precision Peptide Company's product portfolio.</p>
<div class="lb-trans"><p>BPC-157 貼片目前正在積極測試中，預計近期將有結果。若這些測試里程碑順利完成，公司計劃將該產品推進至商業發佈階段，作為精準肽公司產品組合的一部分。</p>
</div><p>For decades, the peptide category has been gated by the needle. While interest in peptides has grown rapidly across recovery, longevity, and broader wellness, the majority of consumers have never crossed the threshold into the category - research consistently identifies needle aversion as a leading barrier to therapies that consumers would otherwise consider. Adoption has therefore skewed toward biohackers, athletes, and clinical populations already comfortable with self-administered injectables.</p>
<div class="lb-trans"><p>數十年來，肽類產品一直受到針頭的限制。儘管在恢復、長壽和更廣泛的健康領域對肽的興趣迅速增長，但大多數消費者從未跨越進入這一領域的門檻——研究一致表明，針頭恐懼是消費者本可以考慮的療法的主要障礙。因此，採用者主要集中在已經習慣自我注射的生物黑客、運動員和臨牀人羣中。</p>
</div><p>The innovative patch is designed to remove that barrier entirely. Worn directly on the skin and precision-engineered for controlled, sustained peptide delivery, the patch eliminates the reconstitution, sterile handling, and dose measurement associated with injectable peptide therapies. The result is a wearable, mainstream-ready format intended to bring BPC-157 and other formulas to consumers who have followed the rise of peptides from a distance and have been waiting for a delivery format they would actually use.</p>
<div class="lb-trans"><p>這一創新貼片旨在完全消除這一障礙。直接貼在皮膚上，經過精確設計以實現控制和持續的肽輸送，該貼片消除了與注射肽療法相關的重組、無菌處理和劑量測量。最終結果是一個可穿戴的、適合主流市場的格式，旨在將 BPC-157 和其他配方帶給那些遠觀肽類產品並一直在等待他們實際會使用的輸送格式的消費者。</p>
</div><p>Pratap Sandhu, CEO of The Precision Peptide Company, commented:</p>
<div class="lb-trans"><p>精準肽公司的首席執行官 Pratap Sandhu 評論道：</p>
</div><p>&#34;This is the product that brings peptides into the mainstream. The needle has historically been the single biggest barrier to entry for this category, and removing it fundamentally changes who the customer is. The patch is built for the person who has read the headlines, listened to the podcasts, and decided peptides aren't for them because they aren't willing to inject. We believe it is the bridge between where peptides have come from and the far larger consumer market they can serve, and the progression of testing to date supports our confidence in that path.&#34;</p>
<div class="lb-trans"><p>“這是將肽帶入主流的產品。針頭歷來是這一領域最大的進入障礙，去除它從根本上改變了客户的面貌。該貼片是為那些閲讀過頭條新聞、聽過播客並決定肽不適合他們的人設計的，因為他們不願意注射。我們相信它是肽類產品的起源與更大消費者市場之間的橋樑，而迄今為止的測試進展支持了我們對這一路徑的信心。”</p>
</div><p>Justin Kirkland, Chief Scientific Officer of Amino Innovations, added:</p>
<div class="lb-trans"><p>Amino Innovations 的首席科學官 Justin Kirkland 補充道：</p>
</div><p>&#34;BPC-157 has decades of preclinical research behind it, and translating that molecule from an injectable into a transdermal format is a meaningful piece of formulation work. The patch is engineered to deliver consistently through the skin in a way that performs reliably outside of an injection setting. The data we are generating through this testing programme is what gives us confidence in the patch as a credible, scalable alternative to traditional peptide administration - and, in our view, a real step forward for how the category reaches everyday consumers.&#34;</p>
<div class="lb-trans"><p>“BPC-157 背後有數十年的臨牀前研究，將該分子從注射劑轉化為經皮格式是一項重要的配方工作。該貼片經過設計，能夠以可靠的方式通過皮膚持續輸送，表現出在非注射環境下的可靠性。我們通過這一測試項目生成的數據使我們對該貼片作為傳統肽給藥的可信、可擴展替代品充滿信心——在我們看來，這是該類別如何接觸日常消費者的一大進步。”</p>
</div><p>The BPC-157 patch is the first product to advance from the Company's broader transdermal patch pipeline. A second patch - the Company's Immune Defense Patch, formulated with Thymosin Alpha-1 (TA-1) and developed on the same delivery platform - is also under development, and is expected to follow BPC-157 through testing and toward commercial readiness in due course. Together, the two products are intended to establish the foundation of a multi-product needle-free peptide platform under the Amino Innovations brand.</p>
<div class="lb-trans"><p>BPC-157 貼片是公司更廣泛的經皮貼片管道中首個推進的產品。第二個貼片——公司的免疫防禦貼片，採用胸腺素 Alpha-1 (TA-1) 配方，並在相同的輸送平台上開發，也在開發中，預計將在測試後跟隨 BPC-157 走向商業準備。兩個產品共同旨在建立一個無針肽類產品的多產品平台，隸屬於 Amino Innovations 品牌。</p>
</div><p>Patch development is supported by the Company's previously announced research services agreement with the Drug Development and Innovation Centre (DDIC) at the University of Alberta, where Dr. Neal Davies and Dr. Raimar Loebenberg, senior professors in the Faculty of Pharmacy and Pharmaceutical Sciences, provide scientific expertise across absorption, bioavailability, and stability work relevant to the Company's peptide portfolio.</p>
<div class="lb-trans"><p>貼片開發得到了公司之前與阿爾伯塔大學藥物開發與創新中心 (DDIC) 簽署的研究服務協議的支持，Neal Davies 博士和 Raimar Loebenberg 博士是藥學與藥物科學學院的高級教授，提供與公司肽產品組合相關的吸收、生物利用度和穩定性方面的科學專業知識。</p>
</div><p>The BPC-157 patch will sit alongside the Company's existing oral peptide product line, manufactured in an approved U.S. facility and distributed across North America through the Amino Innovations brand.</p>
<div class="lb-trans"><p>BPC-157 貼片將與公司現有的口服肽產品線並列，該產品線在美國獲得批准的設施中生產，並通過 Amino Innovations 品牌在北美分銷。</p>
</div><p>There is no assurance that the testing currently underway will produce results that satisfy the Company's internal benchmarks, that the BPC-157 patch or the Immune Defense Patch will be commercialised on the timelines currently contemplated, or that any subsequent product launch will result in revenue or other benefit to the Company. The Company will provide further updates as material developments occur.</p>
<div class="lb-trans"><p>目前正在進行的測試無法保證會產生滿足公司內部基準的結果，BPC-157 貼片或免疫防禦貼片是否會在當前預期的時間表上商業化，或任何後續產品發佈是否會為公司帶來收入或其他利益。公司將在發生重大進展時提供進一步更新。</p>
</div><p><strong>About The Precision Peptide Company</strong></p>
<div class="lb-trans"><p><strong>關於精準肽公司</strong></p>
</div><p>The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the Company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.</p>
<div class="lb-trans"><p>精準肽公司 (CSE: BPC) (OTCQB: PNGAF) 是一家上市健康公司，正在建立一個高質量肽配方的下一代平台。通過結合科學配方和創新輸送技術，公司創造出位於生物技術與可擴展消費者健康交匯處的產品。產品在美國獲得批准的設施中生產，並在北美分銷。</p>
</div><p>For more information, visit: www.precisionpeptidecompany.com</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問：www.precisionpeptidecompany.com</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Information</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性信息的警示説明</strong></p>
</div><p><strong>This news release contains &#34;forward-looking information&#34; within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements relating to: the anticipated timing and outcome of testing of the BPC-157 transdermal patch; the Company's intention to progress the BPC-157 patch toward commercial release; the anticipated development and commercialization of the Immune Defense Patch; the establishment of a multi-product needle-free peptide platform under the Amino Innovations brand; and the expected benefits of the Company's research services agreement with the Drug Development and Innovation Centre (DDIC) at the University of Alberta.</strong></p>
<div class="lb-trans"><p><strong>本新聞稿包含適用的加拿大證券法意義上的 “前瞻性信息”。前瞻性信息包括但不限於與以下內容相關的聲明：對 BPC-157 透皮貼片測試的預期時間和結果；公司推進 BPC-157 貼片商業發佈的意圖；免疫防禦貼片的預期開發和商業化；在 Amino Innovations 品牌下建立多產品無針肽平台；以及公司與阿爾伯塔大學藥物開發與創新中心（DDIC）研究服務協議的預期收益。</strong></p>
</div><p><strong>Forward-looking information is based on certain key expectations and assumptions made by the Company, including that: testing of the BPC-157 patch will proceed on the timelines currently contemplated and will produce results consistent with the Company's internal benchmarks; no adverse regulatory, scientific, manufacturing, or supply chain developments will materially delay or prevent commercialization of the Company's products; the research services agreement with the DDIC will continue in its current form; and general business and economic conditions will not change in a manner materially adverse to the Company.</strong></p>
<div class="lb-trans"><p><strong>前瞻性信息基於公司做出的某些關鍵期望和假設，包括：BPC-157 貼片的測試將按照當前設想的時間表進行，併產生與公司內部基準一致的結果；沒有不利的監管、科學、製造或供應鏈發展會實質性延遲或阻止公司產品的商業化；與 DDIC 的研究服務協議將繼續保持當前形式；以及一般商業和經濟條件不會以對公司不利的方式發生變化。</strong></p>
</div><p><strong>Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, but not limited to: the risk that testing of the BPC-157 patch does not produce satisfactory results; the risk that the Company is unable to commercialize the BPC-157 patch or the Immune Defense Patch on the timelines currently contemplated, or at all; the risk that the transdermal delivery of BPC-157 does not achieve adequate bioavailability or consumer acceptance; and the risk that any subsequent product launch does not result in revenue or other benefit to the Company.</strong></p>
<div class="lb-trans"><p><strong>儘管公司相信前瞻性信息所基於的期望和假設是合理的，但不應對前瞻性信息過度依賴，因為公司無法保證這些信息將被證明是正確的。由於前瞻性信息涉及未來事件和條件，其本質上涉及固有的風險和不確定性。實際結果可能因多種因素和風險而與當前預期大相徑庭，包括但不限於：BPC-157 貼片測試未能產生令人滿意的結果的風險；公司無法在當前設想的時間表內，或根本無法商業化 BPC-157 貼片或免疫防禦貼片的風險；BPC-157 的透皮給藥未能實現足夠的生物利用度或消費者接受度的風險；以及任何後續產品發佈未能為公司帶來收入或其他收益的風險。</strong></p>
</div><p><strong>The forward-looking information contained in this news release is made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.</strong></p>
<div class="lb-trans"><p><strong>本新聞稿中包含的前瞻性信息截至本日期發佈，公司沒有義務公開更新或修訂任何前瞻性信息，無論是由於新信息、未來事件還是其他原因，除非適用的證券法要求。</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8944/296392_c538c1950414bba7_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/8944/296392_c538c1950414bba7_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296392</p>
<div class="lb-trans"><p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/296392</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296392/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/296392/375"/></p>

The Precision Peptide Company Nears Commercial Launch of Needle-Free BPC-157 Patch as Final Testing Advances | PNGAF Stock News

StockTitan

Praxis Precision Medicines

標普生物技術 3 倍做多 - Direxion

美國制藥 ETF - iShares

Invesco Nasdaq Biotechnology ETF

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 ETF - SPDR

基因改革 ETF - ARK

納斯達克生物科技指數 ETF - iShares Nasdaq

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

精密肽公司在無針 BPC-157 貼片的商業發佈上取得進展，最終測試正在推進 | PNGAF 股票新聞